PTCHF — PureTech Health plc
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1782999 ·
Last close
$1.54
Market Cap
$377.82M
52W High
$1.92
52W Low
$1.53
ADV30
377
Next earnings
2026-09-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 637,278,000 | 121,275,000 | 257,789,000 |
| Dec 2025 | — | — | — | — | 534,710,000 | 252,470,000 | 229,034,000 |
| Jun 2025 | — | — | — | — | 553,242,000 | 260,604,000 | 184,217,000 |
| Dec 2024 | — | — | — | — | 602,635,000 | 280,641,000 | 194,702,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,231,000
Inventory
—
Receivables
—
ST Investments
$24,829,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,659,000
EBITDA
$-96,830,000
Free Cash Flow
$-89,990,376
Enterprise Value
$309,904,736
Total Cash
$288,716,000
Total Debt
$203,256,000
Shares Out
245,179,646
Trailing EPS
$-0.46
Book Value
$1.29
ROE
-30.9%
ROA
-10.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,659,000 | -98,525,000 | -109,739,000 | 534,710,000 | 229,034,000 | 312,073,000 | -85,131,000 |
| Dec 2024 | 4,315,000 | -136,095,000 | 53,510,000 | 602,635,000 | 194,702,000 | 414,707,000 | -134,369,000 |
| Dec 2023 | 750,000 | -146,201,000 | -65,697,000 | 693,973,000 | 235,742,000 | 464,066,000 | -105,917,000 |
| Dec 2022 | 2,090,000 | -197,806,000 | -50,354,000 | 702,647,000 | 155,058,000 | 542,220,000 | -178,792,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | $377.47M | $12.96 | — |
| IRD | Opus Genetics, Inc. | $381.04M | $4.58 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $384.01M | $3.60 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $370.35M | $13.03 | — |
| RZLT | Rezolute, Inc. | $387.86M | $4.01 | — |
News headlines (Yahoo Finance, 1h cache)
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 19:00 · Yahoo
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
2026-09-30 11:00 · Yahoo
PureTech Health H1 Earnings Call Highlights
2026-09-22 10:03 · Yahoo
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplast
2026-09-21 06:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
2026-09-09 17:13 · Yahoo
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
2026-08-25 11:05 · Yahoo
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
2026-08-25 11:00 · Yahoo
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
2026-05-01 08:26 · Yahoo
PureTech Health H2 Earnings Call Highlights
2026-04-29 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.